Key result
Non-vitamin K antagonist oral anticoagulants (NOACs) appear to offer similar efficacy and safety for stroke prevention in atrial fibrillation patients regardless of concomitant heart failure.
This review highlights the potential of NOACs as effective and safe alternatives to vitamin K antagonists for stroke prevention in patients with concurrent heart failure and atrial fibrillation, while noting ongoing research for HF patients in sinus rhythm.
No takes yet. Share an insight, caveat, or question.
Supports NOAC use for stroke prevention in AF with or without HF; confirms consistent efficacy and safety across heart failure status in randomized data.
Ferreira et al. (2016) conducted a review in Heart failure with and without atrial fibrillation. Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Vitamin K antagonists was evaluated. Non-vitamin K antagonist oral anticoagulants (NOACs) appear to offer similar efficacy and safety for stroke prevention in atrial fibrillation patients regardless of concomitant heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: